Xenon Pharmaceuticals Inc. XENE
Nov 4, 2026, 2:58 PM EST
- YTD
- -12.83%
- 1 year
- -0.05%
- Market cap
- 3.78B
- EPS (ttm)
- -4.74
- Shares out
- 96.84M
- Forward P/E
- -8.13
- YTD return
- -12.83%
- 1-year return
- -0.05%
- Volume
- 1.06M
- Avg volume
- 1.55M
- Open
- 39.41
- Previous close
- 38.23
- Day's range
- 38.47 – 39.58
- 52-week range
- 33.38 – 72.66
- Beta
- 0.08
- Analysts
- Strong Buy
- Price target
- 71.75 (+83.6%)
- Earnings date
- Nov 9, 2026
1Y +0.42 (+1.09%)
Key statistics
- Enterprise value
- 2.72B
- PEG ratio
- 0.00
- Price / book
- 2.98
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -203.55M
- Total cash
- 930.69M
- Total debt
- 6.42M
- Return on equity
- -43.62%
- Short % of float
- 7.60%
- 50-day average
- 44.88
- 200-day average
- 52.35
Analyst view
Consensus: strong buy
- Target (low)
- 46.00
- Target (mean)
- 71.75
- Target (high)
- 90.00
- Strong buy3
- Buy14
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -1.14.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -1.13 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -1.14 | -1.11 | +0.03 | +2.63% |
| May 7, 2026 | Mar 31, 2026 | -1.17 | -1.17 | 0.00 | 0.00% |
| Feb 26, 2026 | Dec 31, 2025 | -1.20 | -1.31 | -0.11 | -9.17% |
| Nov 3, 2025 | Sep 30, 2025 | -1.16 | -1.15 | +0.01 | +0.86% |
| Aug 11, 2025 | Jun 30, 2025 | -1.03 | -1.07 | -0.04 | -3.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 18, 2026 | Wedbush | main | Outperform | Outperform |
| Sep 18, 2026 | Wells Fargo | main | Overweight | Overweight |
| Sep 18, 2026 | Deutsche Bank | down | Buy | Hold |
| Sep 18, 2026 | Needham | main | Buy | Buy |
| Sep 18, 2026 | Baird | main | Outperform | Outperform |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- xenon-pharma.com
News
Xenon to Present at Upcoming Investor Conferences 
Xenon to Report Q3 2026 Financial Results on November 9, 2026 
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain 
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain 
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors 
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? 
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call 
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On 
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Your note
Sign in to keep a note on XENE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CANNON GILLIAN | Director | Sale | Jun 4, 2026 | 1,455 |
| DIFABIO ANDREA | Officer | Sale | Mar 12, 2026 | 7,301 |
| GANNON STEVEN | Director | Sale | Aug 10, 2026 | 1,870 |
| GAROFALO ELIZABETH AMY M.D. | Director | Conversion of Exercise of derivative security | May 31, 2026 | 2,645 |
| GOVER JUSTIN DAVID | Director | Conversion of Exercise of derivative security | May 31, 2026 | 2,645 |
| KELLY THOMAS PATRICK | Chief Financial Officer | Purchase | Sep 29, 2026 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 9.98% | 9,647,998 | 368.84M | Jun 29, 2026 |
| Blackrock Inc. | 7.78% | 7,522,482 | 287.58M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.98% | 5,777,777 | 220.88M | Jun 29, 2026 |
| Polar Capital Holdings PLC | 4.73% | 4,570,556 | 174.73M | Jun 29, 2026 |
| Driehaus Capital Management, LLC | 4.57% | 4,418,557 | 168.92M | Jun 29, 2026 |
| Jupiter Topco LLC | 4.33% | 4,186,519 | 160.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.91% | 2,814,992 | 107.62M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.81% | 2,718,334 | 103.92M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 2,537,750 | 97.02M | Sep 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.32% | 1,274,673 | 48.73M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.11% | 1,074,458 | 41.08M | Aug 30, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.00% | 962,101 | 36.78M | Jun 29, 2026 |